Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis. Our real-world-evidence multicenter study aims to evaluate the efficacy of bimekizumab in nail psoriasis. (2) Methods: A retrospective analysis of a multicenter observational study included 834 patients affected by moderate-to-severe psoriasis, in 33 Dermatologic Units in Italy, treated with bimekizumab from December 2022 to September 2023. Clinimetric assessments were based on Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Physician's Global Assessment of Fingernail Psoriasis (PGA-F) for the severity of nail psoriasis at 0, 12, 24, and 36 weeks. (3) Results: Psoriatic nail involvement was present in 27.95% of patients. The percentage of patients who achieved a complete clearance of NP in terms of PGA-F 0 was 31.7%, 57%, and 88.5% at week 4, 16, and 36, respectively. PASI 100 was achieved by 32.03% of patients at week 4, by 61.8% at week 16, and by 78.92% of patients at week 36. The mean baseline PASI was 16.24. The mean DLQI values for the entire group of patients at baseline, at week 4, at week 16, and at week 36 were 14.62, 3.02, 0.83, and 0.5, respectively. (4) Conclusions: Therapies that promote the healing of both the skin and nails in a short time can also ensure a lower risk of subsequently developing arthritis which is disabling over time. Bimekizumab proved to be particularly effective to treat NP, with a fast response in terms of complete clearance, with over 88.5% of patients free from NP after 36 weeks. The findings of our real-world study showed that patients with moderate-to-severe PsO and concomitant NP had significantly faster and more substantial improvements in NP up to 36 weeks with respect to previous research findings. Considering the rapid healing of the nail, the dual inhibition of IL17 A and F might have a great value in re-establishing the dysregulation of keratin 17 at the nail level.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2024-10-16
DOI
https://doi.org/10.3390/ph17101378
Citations
5
Primary Topic
Nail Diseases and Treatments
Type
article
Field-Weighted Citation Impact
1.93
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

Giovanni Pellacani, Diego Orsini, Luca Bianchi, Angelo Valerio Marzano et al.
5 citations
Pharmaceuticals
Nail Diseases and Treatments
1.93
article

Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

Giovanni Pellacani, Diego Orsini, Luca Bianchi, Angelo Valerio Marzano, Simone Ribero, Agostina Legori, Giovanni Paolino, Francesco Loconsole, Edoardo Mortato, Maria Esposito, Annunziata Dattola, Luigi Gargiulo, Matteo Megna, Claudio Guarneri, Emanuele Trovato, Andrea Conti, Piergiorgio Malagoli, Enzo Errichetti, Anna Campanati, Franco Castelli, Antônio Rossi, Paolo Dapavo, Chiara Assorgi, Nicoletta Bernardini, Aldo Cuccia, Fabio Artosi, Marina Venturini, Ruslana Gaeta Shumak, Massimo Donini, Santo Raffaele Mercuri, Valentina Dini, Antonio Costanzo, Antonio Giovanni Richetta, Anna Balato, Maria Concetta Fargnoli, Anna Maria Offidani, Martina Burlando, Concetta Potenza, Vito Giuseppe Di Lernia, Carmen Fiorella, Pietro Quaglino, Giuseppe Argenziano, Giacomo Caldarola, Andrea Carugno, Alessandro Giunta, Clara De Simone, Marco Romanelli, Giuseppe Micali, Alessandra Narcisi, Francesca Prignano, Alexandra Maria Giovanna Brunasso, Elena Campione, Paolo Gisondi, Ketty Peris, Maria Letizia Musumeci, Antonio Foti, Davide Strippoli, Serena Lembo
article en
5 citations

Abstract

(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis. Our real-world-evidence multicenter study aims to evaluate the efficacy of bimekizumab in nail psoriasis. (2) Methods: A retrospective analysis of a multicenter observational study included 834 patients affected by moderate-to-severe psoriasis, in 33 Dermatologic Units in Italy, treated with bimekizumab from December 2022 to September 2023. Clinimetric assessments were based on Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Physician's Global Assessment of Fingernail Psoriasis (PGA-F) for the severity of nail psoriasis at 0, 12, 24, and 36 weeks. (3) Results: Psoriatic nail involvement was present in 27.95% of patients. The percentage of patients who achieved a complete clearance of NP in terms of PGA-F 0 was 31.7%, 57%, and 88.5% at week 4, 16, and 36, respectively. PASI 100 was achieved by 32.03% of patients at week 4, by 61.8% at week 16, and by 78.92% of patients at week 36. The mean baseline PASI was 16.24. The mean DLQI values for the entire group of patients at baseline, at week 4, at week 16, and at week 36 were 14.62, 3.02, 0.83, and 0.5, respectively. (4) Conclusions: Therapies that promote the healing of both the skin and nails in a short time can also ensure a lower risk of subsequently developing arthritis which is disabling over time. Bimekizumab proved to be particularly effective to treat NP, with a fast response in terms of complete clearance, with over 88.5% of patients free from NP after 36 weeks. The findings of our real-world study showed that patients with moderate-to-severe PsO and concomitant NP had significantly faster and more substantial improvements in NP up to 36 weeks with respect to previous research findings. Considering the rapid healing of the nail, the dual inhibition of IL17 A and F might have a great value in re-establishing the dysregulation of keratin 17 at the nail level.

PharmaceuticalsVol. 17(10)
University of Siena (IT), Università Cattolica del Sacro Cuore (IT), University of Messina (IT), University of Insubria (IT), University of Rome Tor Vergata (IT), University of Verona (IT), Marche Polytechnic University (IT), University of Udine (IT), University of Salerno (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), University of L'Aquila (IT), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Catania (IT), Ospedale Santa Chiara (IT), IRCCS Policlinico San Donato (IT), IRCCS Ospedale Galeazzi - Sant'Ambrogio (IT), Alessandro Manzoni Hospital (IT), Ospedale Koelliker (IT), Ospedale Santa Maria (IT), IRCCS Ospedale San Raffaele (IT), San Gallicano Hospital (IT), Ospedale San Donato (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Villa Torri Hospital (IT), IRCCS Humanitas Research Hospital (IT), University of Florence (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), University of Brescia (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 13%
Nail Diseases and Treatments
1.93
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.